Abstracts tagged "Patient reported outcomes"

Abstract Number: 1380 • ACR Convergence 2021
Quality of Life in Patients with Scleroderma Associated Calcinosis Cutis: A Cross-Sectional Study
Aditi Patel¹, Mehnaj Grewal², Robert Butler² and Soumya Chatterjee³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Calcinosis cutis (CC) can commonly affect patients with systemic sclerosis (SSc), which is often painful, resulting in functional impairment and morbidity. A radiographic scoring…
Abstract Number: 1672 • ACR Convergence 2021
Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA
Susan Bartlett¹, Dana DiRenzo², Michelle Jones³ and Clifton Bingham², ¹McGill University, Montréal, QC, Canada, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Rheumatic diseases (RD) are chronic conditions that require potent immunosuppressants to control systemic inflammation. Fears associated with increased vulnerability from being on immunosuppressants plus…
Abstract Number: 0145 • ACR Convergence 2021
Rheumatology Provider Perspectives on Using Patient-Reported Outcomes in Clinical Care
Yomei Shaw¹, Neda Kortam², Adam Chalak², Yujia Li², Faith Reger², Vivek Nagaraja² and Dinesh Khanna², ¹University of Michigan, East Lansing, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Patient-reported outcomes (PROs) are surveys completed by patients to provide measurements of health, quality of life, symptoms, and functional status. PROs are useful for…
Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Alain Lescoat¹, Susan Murphy², Yen Chen³, Nadia Vann¹, David Cella⁴ and Dinesh Khanna³, ¹Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Grosse Ile, MI, ³University of Michigan, Ann Arbor, MI, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
Abstract Number: 0743 • ACR Convergence 2021
Pain Interference, Fatigue, Physical Function as Outcome Measures in Adult Myositis: Updates on the Validation Process by the OMERACT Myositis Working Group
Dana DiRenzo¹, Ingrid de Groot², Helene Alexanderson³, Clifton Bingham¹, Ingrid E Lundberg⁴, Merrilee Needham⁵, Jin Kyun Park⁶, Malin Regardt³, Catherine Sarver⁷, Didem Saygin⁸, Yeong-Wook Song⁶, Lara Maxwell⁹, Dorcas Beaton¹⁰, Lisa Christopher-Stine¹ and Christopher Mecoli¹¹, ¹Johns Hopkins University, Baltimore, MD, ²patient research partner, Rotterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵Murdoch University, Perth, Australia, ⁶Seoul National University Hospital, Seoul, Republic of Korea, ⁷patient research partner, Baltimore, MD, ⁸University of Chicago, Chicago, IL, ⁹University of Ottawa, Ottawa, ON, Canada, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: People living with idiopathic inflammatory myositis (IIM) suffer impairments in health-related quality of life (HRQL), especially in the domains of pain interference, fatigue, and…
Abstract Number: 0766 • ACR Convergence 2021
Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort
Jessica Neely¹, Kaveh Ardalan², Adam Huber³ and Susan Kim⁴, ¹University of California San Francisco, San Francisco, CA, ²Duke University Medical Center, Durham, NC, ³Dalhousie University, Halifax, NS, Canada, ⁴UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of children, is rare, with an estimated incidence of 2-4 in 1 million children. Given the…
Abstract Number: 0909 • ACR Convergence 2021
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Current studies suggest that the phenotype of spondyloarthritis differs between genders and that this may influence the subsequent diagnostic approach and therapeutic decisions1. The…
Abstract Number: 1233 • ACR Convergence 2021
Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Edward Keystone³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ³Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as an alternative option to biologic disease modifying antirheumatic drugs…
Abstract Number: 1418 • ACR Convergence 2021
Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Yannick van Sleen¹, Kornelis van der Geest², Annemieke Boots², Maria Sandovici² and Elisabeth Brouwer², ¹University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often overlapping inflammatory diseases that occur in people older than 50 years. Both diseases can…
Abstract Number: 1673 • ACR Convergence 2021
Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions
Orit Schieir¹, Susan Bartlett², Marie-France Valois², Louis Bessette³, Gilles Boire⁴, Glen Hazlewood⁵, Carol Hitchon⁶, Edward Keystone⁷, Janet Pope⁸, Diane Tin⁹, Carter Thorne¹⁰, Vivian Bykerk¹¹ and CATCH Investigators¹², ¹Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: During the COVID-19 pandemic, Canadians adults with RA faced considerable uncertainty due to greater risk of infection, hospitalization, changing access to RA medications, and…
Abstract Number: 0223 • ACR Convergence 2021
The Association of Clinical and Structural Knee Osteoarthritis with Physical Activity in the Middle-aged Population: The Netherlands Epidemiology of Obesity Study
Sietse Terpstra¹, Jeroen van der Velde¹, Renée de Mutsert¹, Dieuwke Schiphof², Monique Reijnierse¹, Frits Rosendaal¹, Lotte van de Stadt¹, Margreet Kloppenburg¹ and Marieke Loef¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Physical activity is a potential target for interventions in knee OA. However, most of the available studies concerning physical activity in individuals with knee…
Abstract Number: 0415 • ACR Convergence 2021
Utility of the 22-Item Sinonasal Outcome Test Patient-Reported Outcome Instrument in ANCA-Associated Vasculitis
Ellen Romich, Sherry Chou and Rennie Rhee, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) causes sinus symptoms that impact quality of life. The 22-item Sinonasal Outcome Test (SNOT-22) is a patient-reported outcome measure to assess…
Abstract Number: 0744 • ACR Convergence 2021
MDHAQ (Multidimensional Health Assessment Questionnaire) and PROMIS-29 (patient-reported Outcomes Measurement Information System) Domains for Physical Function, Pain, Fatigue, Anxiety, Depression, Sleep, and Ability to Participate Provide Virtually Identical Information
Kathryn Gibson¹, Tengfei Li², George Luta² and Theodore Pincus³, ¹Liverpool Hospital, Sydney, Australia, ²Georgetown University, Washington, DC, ³Rush University Medical Center, Chicago, IL
Background/Purpose: PROMIS-29 (patient-reported outcome measurement information system) has been extensively validated in many diseases according to standard deviations from normalized T-scores for 7 domains. It…
Abstract Number: 0771 • ACR Convergence 2021
Race, Ethnicity and Patient-Reported Outcomes in Childhood-Onset Systemic Lupus Erythematosus
R. Ezequiel Borgia¹, Matthew Gurka², Stephanie Filipp², Melissa Elder³, Michelle Cardel² and Natalie Shiff⁴, ¹Department of Pediatrics, University of Florida, Gainesville, FL, USA. Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, ²Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, ³Division of Pediatric Allergy, Immunology and Rheumatology, Department of Pediatrics, University of Florida, Gainesville, FL, ⁴University of Saskatchewan, Department of Community Health and Epidemiology, Saskatoon, SK, Canada. Janssen Scientific Affairs, LLC, Horsham, PA., Gainesville, FL
Background/Purpose: The association of race/ethnicity with childhood-onset systemic lupus erythematosus (cSLE) outcomes has been well described, with non-White individuals experiencing a more severe disease phenotype…
Abstract Number: 0977 • ACR Convergence 2021
Enhancement of Patient and Clinician Partnerships in Juvenile Idiopathic Arthritis Management Using a Point-of-Care Dashboard: Development and Pilot Testing
Erica Lawson¹, Lisa Johnson², Jabeen Ahmad², Vincent Del Gaizo³, Brittany Donaldson⁴, Julie Eller⁵, Yukiko Kimura⁶, Cathy Knucken⁷, Tzielan Lee⁸, Corinne Pinter⁹, Doreen Tabussi¹⁰, Alysha Taxter¹¹ and Aricca Van Citters², ¹University of California San Francisco, San Francisco, CA, ²Dartmouth College, Lebanon, NH, ³Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁴Wake Forest University School of Medicine Brenner Children's, Winston Salem, NC, ⁵Arthritis Foundation, Washington, DC, ⁶Hackensack University Medical Center, New York, NY, ⁷Patient Partner, Byram, NJ, ⁸Stanford University School of Medicine, Palo Alto, CA, ⁹Patient Partner, Sugar Land, TX, ¹⁰Hackensack University Medical Center, Upper Saddle River, NJ, ¹¹Wake Forest Baptist Medical Center, Winston-Salem, NC
Background/Purpose: Health outcomes improve when people living with chronic conditions partner with their clinicians to coproduce care based on their values, preferences, goals, and the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.